SUMMARY Long-term effects on lung size and lung mechanics were sought in a 12-month follow-up study of 15 infants of very low birthweight ( < 1500 g), 7 of whom had been exposed to antepartum dexamethasone (mean dose 21 mg). None of the infants had significant neonatal respiratory disease. No differences were found between dexamethasone-treated and control groups for thoracic gas volume, dynamic pulmonary compliance, or airways resistance during the first year of life. This suggests that the growth and development of the lungs are not adversely affected by antepartum exposure to dexamethasone.
The value of antenatal corticosteroid administration in the prevention of the respiratory distress syndrome in preterm infants has become generally accepted since the work of Liggins and Howie.1 Nevertheless, there is disquieting experimental evidence of adverse effects on the growth of newborn animals after intrauterine or neonatal exposure to corticosteroids.2-4 In particular Johnson and colleagues2 4 have demonstrated in rhesus monkeys that alterations in neonatal lung growth and mechanics may occur after only 3 days of antepartum betamethasone administration in a dose comparable with that used in human obstetric practice. The pulmonary effects appeared to be dose related. 2 Ill effects have been reported for other animal species. 3 This paper reports the results of lung function tests in a group of 15 infants of very low birthweight (VLBW; less than 1500 g), 7 of whom had been exposed to perinatal corticosteroids. We sought evidence for any alteration in lung growth or mechanics during the first year of life that could have been associated with corticosteroid therapy.
Patients
During a prospective longitudinal study of the pulmonary sequelae of VLBW infants, we identified 15 infants who had little or no neonatal lung disease. Five had transient tachypnoea,5 requiring a brief period of added oxygen therapy. Two were mechanically ventilated by endotracheal tube for 15 and 24 hours, during transport and during and after operation for small-bowel resection, respectively.
The mothers of 7 of the infants had been given intramuscular dexamethasone (mean dose 21-1 mg) 536 during the 4 days before delivery, the first dose having been given a mean of 37 hours before delivery. One of the mothers had received only 4 mg, whereas the other 6 had all received at least 12 mg dexamethasone. None of the other 8 infants had been exposed to corticosteroids. The mean birthweight and gestational age6 were significantly greater in the control group, which contained a high proportion of growthretarded infants ( Table 1) . The infants were studied, as far as possible, at 6-monthly intervals for up to 12 months. The older infants were sedated (trichloryl 100 mg/kg) for whole-body plethysmography. Parental consent was obtained for the measurements, which were approved by the Research Ethics Committee.
Methods
In order to measure lung mechanics, the infant was placed in the right lateral position inside the plethysmograph. Once the infant was sleeping quietly, an oesophageal balloon catheter was inserted The relationship between lung volume (TGV) and body weight was so close for the two groups that the regression lines could not be separately depicted (Figure) . The values of lung volume were identical with those obtained in a control group of infants of > 1500 g birthweight studied in this laboratory (TGV (ml) = 14-5 x body weight (kg) + 41-9). Growth-retarded infants had the same relationship between TGV and body weight as did the appropriately grown infants. There was no significant difference between the two groups for either dynamic compliance or airways conductance, normalised for lung volume (Table 2) .
Discussion
The VLBW infants in this study had neonatal lung disease. Other VLBW infants, some exposed antenatally to dexamethasone and who developed neonatal respiratory disease, were of course admitted to our neonatal unit during the same period. They were not included in this study, since it would have been impossible to distinguish possible effects of dexamethasone from the effects of neonatal respiratory disease and its treatment.
No differences in TGV or lung mechanics were detected during the first year of life, between the control and dexamethasone-treated patients. Nor were any dose-related effects discernible when the results for high and low dose dexamethasone-treated infants were compared. The values of lung mechanics were in accord with our own laboratory values for infants of over 1500 g birthweight.
These results in human infants appear to contrast with observations on the lungs of preterm rhesus monkeys exposed in utero to similar amounts of corticosteroids.2 4 In preterm monkeys, betamethasone produced an increase in lung distensibility (compliance) associated with altered alveolar morphology. The functional alterations were detected in saline-filled lungs and were thus independent of surface effects (that is, the surfactant system). It was speculated that long-lasting changes in the mechanical properties of the lungs might have resulted, although long-term follow-up studies were not carried out.
Our earliest studies were made in infants of 3-4 weeks' postnatal age. Moreover, our patients obviously had 'mature' lungs, since none suffered from respiratory disease syndrome. However 
